The Effects of Beta-blockers on Endothelial Nitric Oxide Synthase Immunoreactivity in the Rat Corpus Cavernosum

Urology

Volumn 75, Issue 3, 2010, Pages 589-597

  Dogru, Mehmet Tolga ^a   Aydos, Tolga Reşat ^a   Aktuna, Zuhal ^a   Korkusuz, Petek ^a   Zeybek, Dilara ^a   Görgü, Nart ^b   Korkut, O ǧuzhan ^a   Basar, Mehmet Murad ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CARVEDILOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR; FLUTAMIDE; FULVESTRANT; METOPROLOL; METOPROLOL TARTRATE; NEBIVOLOL; UNCLASSIFIED DRUG; VASOXEN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DILUTION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEEDING; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ENDOTHELIUM; MALE; NITRIC OXIDE SYNTHASE; PENIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN;

EID: 77649183489     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.09.025     Document Type: Article

References (30)

1. Pedersen M.E., and Cockcroft J.R. The vasodilatory beta-blockers. Curr Hypertens Rep 9 (2007) 269-277
2. Hampton J.R. Choosing the right beta-blocker. A guide to selection. Drugs 48 (1994) 549-568
3. Nangle M.R., Cotter M.A., and Cameron N.E. Protein kinase C beta inhibition and aorta and corpus cavernosum function in streptozotocin-diabetic mice. Eur J Pharmacol 475 (2003) 99-106
4. Nangle M.R., Cotter M.A., and Cameron N.E. An in vitro investigation of aorta and corpus cavernosum from eNOS and nNOS gene-deficient mice. Pflugers Arch 448 (2004) 139-145
5. Cockcroft J.R., Chowienczyk P.J., Brett S.E., et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 274 (1995) 1067-1071
6. Lue T.F. Physiology of penile erection and pathophysiology of erectile dysfunction. In: Alan J.W., Louis R.K., Andrew C.N., Alan W.P., and Craig A.P. (Eds). Campbell's Urology. 9th ed. (2007), Saunders Elsevier, Philadelphia, PA 718-741
7. Burnett A.L. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 16 suppl 1 (2004) S15-S19
8. Costa C., and Virag R. The endothelial-erectile dysfunction connection: an essential update. J Sex Med 6 (2009) 2390-2404
9. Vlachopoulos C., Ioakeimidis N., Terentes-Printzios D., et al. The triad: erectile dysfunction-endothelial dysfunction-cardiovascular disease. Curr Pharm Des 14 (2008) 3700-3714
10. Silvestri A., Galetta P., Cerquetani E., et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 24 (2003) 1928-1932
11. Reidenbach C., Schwinger R.H., Steinritz D., et al. Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum. Life Sci 80 (2007) 2421-2427
12. Garbán H.J., Buga G.M., and Ignarro L.J. Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol 43 (2004) 638-644
13. Uǧur Y., Sari O., Uǧur O., et al. Lack of correlation between Tc99m-sestamibi uptake and cadherin expression in infiltrating ductal breast carcinoma as prognostic indicators. Ann Nucl Med 17 (2003) 281-287
14. Goyal H.O., Braden T.D., Williams C.S., et al. Abnormal morphology of the penis in male rats exposed neonatally to diethylstilbestrol is associated with altered profile of estrogen receptor-alpha protein, but not of androgen receptor protein: a developmental and immunocytochemical study. Biol Reprod 70 (2004) 1504-1517
15. Inan S., Vatansever S., Celik-Ozenci C., et al. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol Histopathol 21 (2006) 1055-1064
16. Dessy C., Saliez J., Ghisdal P., et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 112 (2005) 1198-1205
17. Kakoki M., Hirata Y., Hayakawa H., et al. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 33 (1999) 467-471
18. Nakajima T., Ma J., Iida H., et al. Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells. Jpn Heart J 44 (2003) 963-978
19. Grundt C., Meier K., Grundt A., et al. Evidence for an estradiol-agonistic action of nebivolol in spontaneously hypertensive rats. J Hypertens 25 (2007) 1001-1007
20. Ladage D., Reidenbach C., Lichtenthal A., et al. Third generation beta-blockers: current state of research on vasodilating beta-blockers. Wien Med Wochenschr 159 (2009) 211-218
21. Ladage D., Brixius K., Hoyer H., et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol 33 (2006) 720-724
22. Gosgnach W., Boixel C., Nevo N., et al. Nebivolol induces calcium independent signaling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol 38 (2001) 191-199
23. Ignarro L.J., Byrns R.E., Trinh K., et al. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide and cyclic GMP-dependent mechanisms. Nitric Oxide 7 (2002) 75-82
24. Parenti A., Filippi S., Amerini S., et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 292 (2000) 698-703
25. Haynes M.P., Sinha D., Russell K.S., et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87 (2000) 677-682
26. Heinlein C.A., and Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 23 (2002) 175-200
27. Tsai M.J., and O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63 (1994) 451-486
28. Panet-Raymond V., Gottlieb B., Beitel L.K., et al. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 167 (2000) 139-150
29. Yeh S., Miyamoto H., Shima H., et al. From estrogen to androgen receptor: a new pathway for sex hormones in the prostate. Proc Natl Acad Sci U S A 95 (1998) 5527-5532
30. Katzenellenbogen J.A., O'Malley B.W., and Katzenellenbogen B.S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10 (1996) 119-131